These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19423340)

  • 1. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.
    Pepe A; Sun L; Zanardi I; Wu X; Ferlini C; Fontana G; Bombardelli E; Ojima I
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3300-4. PubMed ID: 19423340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
    Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
    Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
    Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
    Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of new-generation taxoids.
    Ojima I; Chen J; Sun L; Borella CP; Wang T; Miller ML; Lin S; Geng X; Kuznetsova L; Qu C; Gallager D; Zhao X; Zanardi I; Xia S; Horwitz SB; Mallen-St Clair J; Guerriero JL; Bar-Sagi D; Veith JM; Pera P; Bernacki RJ
    J Med Chem; 2008 Jun; 51(11):3203-21. PubMed ID: 18465846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Cytotoxicity of 7,9-
    Zhao Y; Wang TE; Mills A; Gago F; Fang WS
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31181726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.
    Yang CH; Wang C; Ojima I; Horwitz SB
    J Nat Prod; 2018 Mar; 81(3):600-606. PubMed ID: 29517223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 2'-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate.
    Battaglia A; Bernacki RJ; Bertucci C; Bombardelli E; Cimitan S; Ferlini C; Fontana G; Guerrini A; Riva A
    J Med Chem; 2003 Nov; 46(23):4822-5. PubMed ID: 14584931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
    Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
    Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
    Ojima I; Slater JC; Michaud E; Kuduk SD; Bounaud PY; Vrignaud P; Bissery MC; Veith JM; Pera P; Bernacki RJ
    J Med Chem; 1996 Sep; 39(20):3889-96. PubMed ID: 8831755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and SAR study of 3rd-generation taxoids bearing 3-CH
    Wang C; Wang X; Sun Y; Taouil AK; Yan S; Botchkina GI; Ojima I
    Bioorg Chem; 2020 Jan; 95():103523. PubMed ID: 31911305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells.
    Fan LL; Chen X; Zhang XY; Li ZM; Fan XM; Shen Y
    Med Sci Monit; 2020 Aug; 26():e922612. PubMed ID: 32829374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and SAR study of Fluorine-containing 3rd-generation taxoids.
    Wang C; Chen L; Sun Y; Guo W; Taouil AK; Ojima I
    Bioorg Chem; 2022 Feb; 119():105578. PubMed ID: 34979464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
    Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
    J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.
    van Ark-Otte J; Samelis G; Rubio G; Lopez Saez JB; Pinedo HM; Giaccone G
    Oncol Rep; 1998; 5(1):249-55. PubMed ID: 9458331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice.
    Chen X; Zhang XY; Shen Y; Fan LL; Ren ML; Wu YP
    Oncotarget; 2016 Dec; 7(50):83451-83461. PubMed ID: 27825139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.